Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Daniel E Meyers"'
Autor:
Kristina Jenei, Daniel E Meyers
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Objective To examine characteristics of clinician input to the pan-Canadian Oncology Drug Review (pCODR) for cancer drug funding recommendations from 2016 to 2020.Design, setting and participants Descriptive, cross-sectional study including 62 reimbu
Externí odkaz:
https://doaj.org/article/a6e14666771b4f44bb1863cdfb5c2d21
Autor:
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, Tina Cheng
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7695-7704 (2022)
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elus
Externí odkaz:
https://doaj.org/article/1f5f9e1739c3404695cccba5ce955721
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 4542-4551 (2021)
Malignant pleural mesothelioma is a rare and aggressive malignancy arising from mesothelial cells that line the serous membranes of the body. Cytotoxic chemotherapy has been a mainstay of therapy, resulting in a modest improvement in overall survival
Externí odkaz:
https://doaj.org/article/0e809a0640d94465843efc77da7bb2b8
Autor:
Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4213-4222 (2021)
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice
Externí odkaz:
https://doaj.org/article/ef1a3db40d2d4a92a300be45448be0e8
Autor:
Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2618-2626 (2021)
Abstract Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to
Externí odkaz:
https://doaj.org/article/912792318bd545cba1e0cd7fc036db6d
Autor:
Steven M. Yip, Daniel E. Meyers, Jeff Sisler, Keith Wycliffe-Jones, Edward Kucharski, Christine Elser, Claire Temple-Oberle, Silvana Spadafora, Paris-Ann Ingledew, Meredith Giuliani, Sara Kuruvilla, Nureen Sumar, Vincent C. Tam
Publikováno v:
BMC Medical Education, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background This study aimed to determine the current state of oncology education in Canadian family medicine postgraduate medical education programs (FM PGME) and examine opinions regarding optimal oncology education in these programs. Metho
Externí odkaz:
https://doaj.org/article/cae1dfba240343e4b985f2e250ee379f
Autor:
Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4640-4647 (2020)
Abstract Background The CELESTIAL, RESORCE, and REACH‐2 trials showed survival benefit of cabozantinib, regorafenib, and ramucirumab, respectively, in hepatocellular carcinoma (HCC) patients treated with sorafenib who had good performance status (E
Externí odkaz:
https://doaj.org/article/f4695cfcaa624e019d0cbdbba425df4f
Autor:
Vishal Navani, Daniel E. Meyers, Yibing Ruan, Devon J. Boyne, Dylan E. O'Sullivan, Samantha Dolter, Heidi AI Grosjean, Igor Stukalin, Daniel Y.C. Heng, Don G. Morris, Darren R. Brenner, Randeep Sangha, Winson Y. Cheung, Aliyah Pabani
Publikováno v:
Clinical Lung Cancer. 24:e152-e159
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21f50a6ddc30ba2b0469bdbe5fd5ac16
https://doi.org/10.1016/j.cllc.2022.12.014
https://doi.org/10.1016/j.cllc.2022.12.014
Autor:
Igor Stukalin, Vishal Navani, Mehul Gupta, Yibing Ruan, Devon J Boyne, Dylan E O’Sullivan, Daniel E Meyers, Siddhartha Goutam, Michael Sander, Benjamin W Ewanchuk, Darren R Brenner, Aleksi Suo, Winson Y Cheung, Daniel Y C Heng, Jose G Monzon, Tina Cheng
Publikováno v:
The Oncologist.
Background Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS). Patients and Methods A total of 318
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fbc6aaee499972aadbfb347e9f60ae7
https://doi.org/10.1093/oncolo/oyad073
https://doi.org/10.1093/oncolo/oyad073
Autor:
Daniel E. Meyers, Meghann Pasternak, Samantha Dolter, Heidi A.I. Grosjean, Chloe A. Lim, Igor Stukalin, Siddhartha Goutam, Vishal Navani, Daniel Y.C. Heng, Winson Y. Cheung, Don G. Morris, Aliyah Pabani
Publikováno v:
JTO Clin Res Rep
INTRODUCTION: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec7446b76036f6ee4e321be7d90b3dc
https://europepmc.org/articles/PMC10120368/
https://europepmc.org/articles/PMC10120368/
